Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr 23;14(5):442.
doi: 10.3390/jpm14050442.

Isolated Limb Perfusion and Immunotherapy in the Treatment of In-Transit Melanoma Metastases: Is It a Real Synergy?

Marco Rastrelli  1   2 , Francesco Russano  1 , Francesco Cavallin  3 , Paolo Del Fiore  1 , Claudia Pacilli  4 , Claudia Di Prata  5 , Carlo Riccardo Rossi  2 , Antonella Vecchiato  1 , Luigi Dall'Olmo  1   2 , Simone Mocellin  1   2
Affiliations

Isolated Limb Perfusion and Immunotherapy in the Treatment of In-Transit Melanoma Metastases: Is It a Real Synergy?

Marco Rastrelli et al. J Pers Med. .

Abstract

Background: Isolated limb hyperthermic-antiblastic perfusion (ILP) was the most effective local treatment for advanced in-transit melanoma, but the advent of modern effective immunotherapy (IT), such as immune checkpoint inhibitors, has changed the treatment landscape.

Methods: This study evaluated the role of the association between ILP and IT in the treatment of locally advanced unresectable melanoma, particularly in relation to modern systemic therapies. We analyzed 187 consecutive patients who were treated with ILP (melphalan or melphalan associated with TNF-alpha) for advanced melanoma at the Veneto Institute of Oncology of Padua (Italy) and the Padua University Hospital (Italy) between June 1989 and September 2021. Overall survival (OS), disease-specific survival (DSS), local disease-free survival (local DFS) and distant disease-free survival (distant DFS) were evaluated. Local toxicity was classified according to the Wieberdink scale and surgical complications according to the Clavien-Dindo classification. Response to locoregional therapy was evaluated during follow-up according to the RECIST 1.1 criteria (Response Evaluation Criteria in Solid Tumor).

Results: A total of 99 patients were treated with ILP and 88 with IT + ILP. The overall response rate was 67% in both groups. At 36 months, OS was 43% in the ILP group and 61% in the ILP + IT group (p = 0.02); DSS was 43% in the ILP group and 64% in the ILP + IT group (p = 0.02); local DFS was the 37% in ILP group and 53% in the ILP + IT group (p = 0.04); and distant DFS was 33% in the ILP group and 35% in the ILP + IT group (p = 0.40). Adjusting for age and lymph node involvement, receiving ILP + IT was associated with improved OS (p = 0.01) and DSS (p = 0.007) but not local DFS (p = 0.13) and distant DFS (p = 0.21).

Conclusions: Our findings confirm the synergy between ILP and IT. ILP remains a valuable loco-regional treatment option in the era of effective systemic treatments. Further studies are needed to establish the optimal combination of loco-regional and systemic treatments and address the best timing of this combination to obtain the highest local response rate.

Keywords: ILP; in-transit melanoma metastases; isolated limb perfusion; metastases in-transit.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Overall survival in ILP vs. IT + ILP groups.
Figure 2
Figure 2
Disease-specific survival in ILP vs. IT + ILP groups.
Figure 3
Figure 3
Local disease-free survival in ILP vs. IT + ILP groups.
Figure 4
Figure 4
Distant disease-free survival in ILP vs. IT + ILP groups.
See this image and copyright information in PMC

References

    1. Perez M.C., Tanabe K.K., Ariyan C.E., Miura J.T., Mutabdzic D., Farma J.M. Local and Recurrent Regional Metastases of Melanoma. In: Balch C.M., Atkins M.B., Garbe C., Gershenwald J.E., Halpern A.C., Kirkwood J.M., McArthur G.A., Thompson J.F., Sober A.J., editors. Cutaneous Melanoma. Springer; Cham, Switzerland: 2020. - DOI
    1. Read R.L., Thompson J.F. The role of regional chemotherapy for advanced limb melanoma in the era of potentially effective systemic therapies. Melanoma Res. 2021;31:290–297. doi: 10.1097/CMR.0000000000000740. - DOI - PubMed
    1. Queiroz M.M., Bertolli E., Belfort F.A., Munhoz R.R. Management of In-Transit Metastases. Curr. Oncol. Rep. 2022;24:573–583. doi: 10.1007/s11912-022-01216-0. - DOI - PubMed
    1. Creech O.J.M., Krementz E.T.M., Ryan R.F.M., Winblad J.N.M. Chemotherapy of cancer: Regional perfusion utilizing an extracorporeal circuit. Ann. Surg. 1958;148:616–632. doi: 10.1097/00000658-195810000-00009. - DOI - PMC - PubMed
    1. Grünhagen D.J., Brunstein F., Graveland W.J., van Geel A.N., de Wilt J.H., Eggermont A.M. One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases. Ann. Surg. 2004;240:939–947; discussion 947–948. doi: 10.1097/01.sla.0000146147.89667.ed. - DOI - PMC - PubMed

LinkOut - more resources